54 related articles for article (PubMed ID: 15344537)
1. Impact of CYP2C19 metabolizer status on esophageal mucosal inflammation, acid exposure, and motility among patients on chronic proton-pump inhibitor therapy with refractory symptoms of gastroesophageal reflux disease.
Tai CC; Medwid S; Mclntosh K; Chande N; Kim RB; Gregor J
J Can Assoc Gastroenterol; 2024 Jun; 7(3):238-245. PubMed ID: 38841142
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the pathophysiological association between the GERD and OSAS: Esophageal pH-monitoring results beyond Lyon criteria.
Barbera L; Pasta A; Calabrese F; Zentilin P; Fragale M; Barbieri M; Peretti G; Savarino EV; Giannini EG; Marabotto E
J Gastroenterol Hepatol; 2024 Apr; 39(4):772. PubMed ID: 38221800
[No Abstract] [Full Text] [Related]
3. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
Furuta T; Shirai N; Watanabe F; Honda S; Takeuchi K; Iida T; Sato Y; Kajimura M; Futami H; Takayanagi S; Yamada M; Ohashi K; Ishizaki T; Hanai H
Clin Pharmacol Ther; 2002 Oct; 72(4):453-60. PubMed ID: 12386647
[TBL] [Abstract][Full Text] [Related]
4. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
5. [Test of refractory gastroesophageal reflux disease].
Shimoyama Y; Kuribayashi S; Maeda M; Kusano M
Nihon Rinsho; 2004 Aug; 62(8):1475-82. PubMed ID: 15344537
[TBL] [Abstract][Full Text] [Related]
6. [Pathogenesis and treatment of refractory gastroesophageal reflux disease in Japanese patients].
Fujiwara Y; Higuchi K; Yamamori K; Watanabe Y; Shiba M; Watanabe T; Tominaga K; Oshitani N; Matsumoto T; Arakawa T
Nihon Rinsho; 2004 Aug; 62(8):1510-5. PubMed ID: 15344542
[TBL] [Abstract][Full Text] [Related]
7. [Management of gastroesophageal reflux disease (GERD) with refractory to standard dose of proton pump inhibitor].
Iwakiri K; Kawami N; Tanaka Y; Sano H; Kotoyori M; Sakamoto C
Nihon Rinsho; 2007 May; 65(5):913-20. PubMed ID: 17511233
[TBL] [Abstract][Full Text] [Related]
8. [PPI: new strategies for GERD].
Hoshino E; Ishiyama A; Tsuchida T
Nihon Rinsho; 2004 Aug; 62(8):1570-6. PubMed ID: 15344553
[TBL] [Abstract][Full Text] [Related]
9. Reflux monitoring: pH-metry, Bilitec and oesophageal impedance measurements.
Pohl D; Tutuian R
Best Pract Res Clin Gastroenterol; 2009; 23(3):299-311. PubMed ID: 19505660
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
